<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03060603</url>
  </required_header>
  <id_info>
    <org_study_id>FSM EAH-KAEK 2016/7</org_study_id>
    <nct_id>NCT03060603</nct_id>
  </id_info>
  <brief_title>Proliferative Effects of Erythropoietin on Human Endometrium</brief_title>
  <official_title>Proliferative Effects of Erythropoietin on Human Endometrium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fatih Sultan Mehmet Training and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dr. Lutfi Kirdar Kartal Training and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fatih Sultan Mehmet Training and Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study to assess the proliferative effects of erythropoetin on human
      endometrium tissue by measuring the endometrial thickness, uterine artery and subendometrial
      blood flow in postmenopausal women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      20 postmenopausal women who are planned to treat with erythropoietin alpha for their renal
      conditions will be included to the study. Sample size was calculated with proper power
      analysis with accepting the difference of 1 mm in endometrial thickness as a significant
      change. After the informed consent, endometrial thickness (mm), uterine artery and
      subendometrial blood flow by doppler ultrasonography (RI, S/D) will be measured. Same
      measurements will be repeated on the 3rd day and 30th day. Patients' age, BMI,
      co-morbidities, administered erythropoietin doses will be noted. No adverse effect is
      expected with regard to the ultrasonographic examination. Date of the patients who do not
      attend for the appointments for repetitive examinations and uninterpretable doppler variables
      due to the atrophic uterus will be noted as the missing data and will be excluded from the
      study. Proper statistical analysis will be done.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 23, 2017</start_date>
  <completion_date type="Actual">January 15, 2018</completion_date>
  <primary_completion_date type="Actual">December 29, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline Endometrial Thickness Confirmed by Transvaginal Ultrasonography at 3th and 30th Days</measure>
    <time_frame>within the first 3 and 30 days (plus or minus 3 days) after the erythropoietin treatment</time_frame>
    <description>Change from Baseline Endometrial Thickness Confirmed by Transvaginal</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">14</enrollment>
  <condition>Anemia</condition>
  <condition>Endometrial Diseases</condition>
  <arm_group>
    <arm_group_label>Erythropoietin</arm_group_label>
    <description>Recombinant Human Erythropoietin, EPREX 4000 IU/0.4 ml, three times in a week, until the correction of anemia, approximately two months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erythropoietin</intervention_name>
    <description>Recombinant Human Erythropoietin, three times in a week, until the correction of anemia, approximately two months.</description>
    <arm_group_label>Erythropoietin</arm_group_label>
    <other_name>Recombinant Human Erythropoietin, EPREX 4000 IU/0.4 ml</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be recruited from a tertiary research clinic, department of nephrology,
        Istanbul, Turkey.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinically condition with need for erythropoietin treatment such as anemia due to the
             renal failure or the need for hemodialysis.

          -  Must be in postmenopausal period

        Exclusion Criteria:

          -  Patients with any type of malignancy

          -  Existence of any intracavitary mass which may affect endometrial thickness or blood
             flow such as endometrial polyps, myomas, intracavitary fluid etc.

          -  Intrauterine device

          -  Being on Hormon replacement therapy

          -  Hysterectomized patients
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Niyazi Tug, Ass.Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Executive and Educational Supervisor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fatih Sultan Mehmet Training and Research Hospital</name>
      <address>
        <city>Istanbul</city>
        <state>Atasehir</state>
        <zip>34758</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Tug N, Altunkaynak ME, Aktas RG, Kilic U, Yilmaz B, Cam C, Karateke A. Does erythropoietin affect motility of spermatozoa? Arch Gynecol Obstet. 2010 May;281(5):933-8. doi: 10.1007/s00404-009-1289-4. Epub 2009 Nov 25.</citation>
    <PMID>19937447</PMID>
  </reference>
  <reference>
    <citation>Tug N, Kilic U, Karateke A, Yilmaz B, Ugur M, Kilic E. Erythropoietin receptor-like immunostaining on human spermatozoa. Reprod Biomed Online. 2010 Nov;21(5):718-20. doi: 10.1016/j.rbmo.2010.05.022. Epub 2010 Jun 19.</citation>
    <PMID>20884294</PMID>
  </reference>
  <reference>
    <citation>Wang L, Di L, Noguchi CT. Erythropoietin, a novel versatile player regulating energy metabolism beyond the erythroid system. Int J Biol Sci. 2014 Aug 23;10(8):921-39. doi: 10.7150/ijbs.9518. eCollection 2014. Review.</citation>
    <PMID>25170305</PMID>
  </reference>
  <reference>
    <citation>Ogilvie M, Yu X, Nicolas-Metral V, Pulido SM, Liu C, Ruegg UT, Noguchi CT. Erythropoietin stimulates proliferation and interferes with differentiation of myoblasts. J Biol Chem. 2000 Dec 15;275(50):39754-61.</citation>
    <PMID>10995753</PMID>
  </reference>
  <reference>
    <citation>Yokomizo R, Matsuzaki S, Uehara S, Murakami T, Yaegashi N, Okamura K. Erythropoietin and erythropoietin receptor expression in human endometrium throughout the menstrual cycle. Mol Hum Reprod. 2002 May;8(5):441-6.</citation>
    <PMID>11994541</PMID>
  </reference>
  <results_reference>
    <citation>Yasuda Y, Masuda S, Chikuma M, Inoue K, Nagao M, Sasaki R. Estrogen-dependent production of erythropoietin in uterus and its implication in uterine angiogenesis. J Biol Chem. 1998 Sep 25;273(39):25381-7.</citation>
    <PMID>9738005</PMID>
  </results_reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2017</study_first_submitted>
  <study_first_submitted_qc>February 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2017</study_first_posted>
  <last_update_submitted>January 18, 2018</last_update_submitted>
  <last_update_submitted_qc>January 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fatih Sultan Mehmet Training and Research Hospital</investigator_affiliation>
    <investigator_full_name>MEHMET AKIF SARGIN</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Erythropoietin</keyword>
  <keyword>Endometrium</keyword>
  <keyword>Doppler Ultrasonography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

